Joe Rogan on health: what the evidence says · JRE #1671

What the evidence says 01 / RECORD

The 58% figure Rogan cites closely matches an unblinded, open-label Argentine trial (Chahla et al.) of household contacts of COVID-19 patients, which reported 7.4% infection in the ivermectin group versus 58.4% in the no-treatment group; that study was assessed as high risk of bias due to lack of blinding, insufficient reporting on randomization and allocation concealment, and PCR confirmation performed on only 16 of 340 participants. A separate, frequently cited Argentine prophylaxis study associated with Dr. Hector Carvallo (sometimes called the IVERCAR protocol) tested ivermectin combined with iota-carrageenan, not ivermectin alone, making it impossible to attribute any protective effect to ivermectin specifically; a related, larger Carvallo observational study used a four-drug combination (ivermectin, enoxaparin, aspirin, and dexamethasone) rather than ivermectin alone. A separate systematic review and meta-analysis of ivermectin prophylaxis trials found inconsistent, low-certainty evidence for COVID-19 prevention. Larger, higher-quality randomized controlled trials of ivermectin for COVID-19 prevention and treatment have not replicated effects of this magnitude. The claimed 0% versus 58% figures therefore likely reflect a high-risk-of-bias, unblinded trial rather than a rigorous prophylaxis RCT, and do not reflect the current weight of controlled-trial evidence on ivermectin as COVID-19 prophylaxis.